GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)
India flag India · Delayed Price · Currency is INR
2,593.90
-73.05 (-2.74%)
At close: Feb 13, 2026

BOM:500660 Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
9,2765,9006,10716,9473,581
Depreciation & Amortization
565.7591.43560.73587.16695.71
Other Amortization
102.22105.3796.9494.790.34
Loss (Gain) From Sale of Assets
15.13-8.89-0.28-3.240.59
Loss (Gain) From Sale of Investments
-696.5-487.76-307.79-5.92-
Provision & Write-off of Bad Debts
23.765.87-73.641.6220.61
Other Operating Activities
1,765-895.67-1,124-11,442-38.93
Change in Accounts Receivable
-728.68-302.69202.28102.04-999.34
Change in Inventory
433.11-650.78747.25120.03-467.93
Change in Accounts Payable
769.691,901-1,5321,0241,074
Change in Other Net Operating Assets
1,374-337.69125.16-47.1850.63
Operating Cash Flow
12,8995,8204,8428,1075,779
Operating Cash Flow Growth
121.63%20.20%-40.27%40.29%17.82%
Capital Expenditures
-230.22-312.22-440.39-346.41-442.27
Sale of Property, Plant & Equipment
57.17224.5614.5711.771,807
Sale (Purchase) of Real Estate
--97.8323.4218.41
Investment in Securities
-1,444-1,4549,563-18,1242,250
Other Investing Activities
1,1591,629-1,15614,080547.26
Investing Cash Flow
-458.0187.128,079-4,0554,180
Long-Term Debt Repaid
-187.31-181.25-168.68-156.18-149.84
Total Debt Repaid
-187.31-181.25-168.68-156.18-149.84
Net Debt Issued (Repaid)
-187.31-181.25-168.68-156.18-149.84
Common Dividends Paid
-7,494-5,416-15,255-5,066-6,770
Other Financing Activities
-13.14-17.99-9.55-19.9-35.31
Financing Cash Flow
-7,694-5,615-15,433-5,242-6,956
Net Cash Flow
4,747292.3-2,512-1,1903,004
Free Cash Flow
12,6695,5084,4027,7615,337
Free Cash Flow Growth
130.01%25.13%-43.28%45.42%59.50%
Free Cash Flow Margin
33.79%15.95%13.54%23.68%18.24%
Free Cash Flow Per Share
74.7832.5125.9845.8131.50
Cash Interest Paid
13.1417.9913.9817.3735.31
Cash Income Tax Paid
823.792,3492,6461,1951,474
Levered Free Cash Flow
11,6246,7011,56210,0973,506
Unlevered Free Cash Flow
11,6326,7121,57310,1093,528
Change in Working Capital
1,848610.21-457.461,199457.46
Source: S&P Global Market Intelligence. Standard template. Financial Sources.